Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients
- PMID: 16528713
- DOI: 10.1002/lt.20655
Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients
Abstract
The severity of recurrent hepatitis C virus (HCV) is likely related to several factors. Controversial results have been reported regarding the effect of specific calcineurin-inhibitors. The aim of this research was to determine whether there are differences on posttransplantation outcome in HCV-infected patients based on initial immunosuppression. Prospective randomized trial comparing tacrolimus vs. cyclosporine-based immunosuppression in a cohort of patients undergoing primary orthotopic liver transplantation between 2001 and 2003 was used. Yearly biopsies were performed. Patients with at least 1 protocol biopsy and those with very severe recurrence despite a follow-up of less than 1 yr (cholestatic hepatitis, progression to bridging fibrosis/cirrhosis) were included. Baseline characteristics (demographics, liver function at transplantation, genotype distribution, donor, surgery, immunosuppression except for the type of calcineurin inhibitor) did not differ between the 2 groups. Severe disease (defined as bridging fibrosis, cirrhosis, cholestatic hepatitis, and/or death due to recurrent disease in the first year) was present in 27 in 90 (30%), and was equally distributed in the cyclosporine and tacrolimus groups (15/46 vs. 12/44, respectively). A total of 33 in 90 (37%) patients had no fibrosis in the first year biopsy with no difference between the cyclosporine and tacrolimus groups (36.5 vs. 37%). The percentage of patients developing recurrent acute hepatitis was also similar (32% vs 35%); time to acute hepatitis though was shorter in the tacrolimus group (59 days [35-185] vs. 92 days [39-343] in the cyclosporin group; P = 0.02). Cholestatic hepatitis was observed in 4 of 44 and 5 of 46 patients under cyclosporine and tacrolimus, respectively (P = not significant). In conclusions, the short-term posttransplantation course of hepatitis C is not related to the calcineurin inhibitor used.
Comment in
-
Recurrent hepatitis C post-liver transplant: the lessons learned.Liver Transpl. 2006 May;12(5):710-2. doi: 10.1002/lt.20751. Liver Transpl. 2006. PMID: 16628696 No abstract available.
Similar articles
-
Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.J Hepatol. 2006 Apr;44(4):717-22. doi: 10.1016/j.jhep.2006.01.005. Epub 2006 Feb 6. J Hepatol. 2006. PMID: 16487616
-
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.Transplantation. 2010 Dec 15;90(11):1204-9. doi: 10.1097/TP.0b013e3181fa93fa. Transplantation. 2010. PMID: 21068701 Clinical Trial.
-
Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.Liver Transpl. 2004 Oct;10(10):1258-62. doi: 10.1002/lt.20222. Liver Transpl. 2004. PMID: 15376310 Clinical Trial.
-
Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.Liver Int. 2004 Oct;24(5):402-6. doi: 10.1111/j.1478-3231.2004.0987.x. Liver Int. 2004. PMID: 15482334 Review.
-
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation.Aliment Pharmacol Ther. 2005 Oct 15;22(8):657-66. doi: 10.1111/j.1365-2036.2005.02662.x. Aliment Pharmacol Ther. 2005. PMID: 16197487 Review.
Cited by
-
A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients.J Transplant. 2012;2012:894215. doi: 10.1155/2012/894215. Epub 2012 May 28. J Transplant. 2012. PMID: 22690326 Free PMC article.
-
Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study.J Clin Transl Hepatol. 2023 Aug 28;11(4):839-849. doi: 10.14218/JCTH.2022.00348. Epub 2023 Mar 7. J Clin Transl Hepatol. 2023. PMID: 37408814 Free PMC article.
-
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review.J Clin Transl Hepatol. 2015 Jun 28;3(2):140-8. doi: 10.14218/JCTH.2015.00005. Epub 2015 Jun 15. J Clin Transl Hepatol. 2015. PMID: 26357641 Free PMC article. Review.
-
The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.Int J Health Sci (Qassim). 2018 Jul-Aug;12(4):78-87. Int J Health Sci (Qassim). 2018. PMID: 30022908 Free PMC article.
-
IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens.Int J Organ Transplant Med. 2010;1(1):7-14. Epub 2010 Feb 1. Int J Organ Transplant Med. 2010. PMID: 25013557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical